AstraZeneca PLC (AZN) vs Johnson & Johnson (JNJ)
- AstraZeneca PLC AZN 165.41 −0.76%
- Johnson & Johnson JNJ 255.55 +0.90%
AstraZeneca PLC and Johnson & Johnson are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $610.4B against $258.5B — 2.4× the size. AstraZeneca PLC trades at the lower P/E: 24.5× against 29.6×. AstraZeneca PLC grew revenue faster over the last twelve months: 8.61% against 7.80%. AstraZeneca PLC has the higher net margin (17.0% vs 16.2%) and the higher return on invested capital (11.7% vs 0.00%). Both pay a dividend; Johnson & Johnson yields more (2.07% vs 1.94%). Across the 23 metrics below, AstraZeneca PLC leads on 16 and Johnson & Johnson on 7.
Valuation
Profitability
| Metric | AZN | JNJ | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.88% | 67.56% | 72.77% |
| Operating margin | 22.77% | 19.29% | 18.77% |
| Net margin | 17.02% | 16.20% | 8.27% |
| Free cash flow margin | 10.21% | 0.00% | 17.18% |
| Return on equity | 21.95% | 0.00% | 5.87% |
| Return on assets | 9.15% | 0.00% | 2.57% |
| Return on invested capital | 11.67% | 0.00% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack